Indeed, when combined with CDDP (or another chemotherapeutic agent such as mitomycin C), crizotinib is effective against s.c. and orthotopic TC1 or LLC1 NSCLC, as well as against more realistic NSCLC models that were either induced by chemical carcinogenesis or by the conditional activation of mutant Kras and deleted Trp53. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.